ArticleJournal of virology2025
Interferon-induced miR-7705 modulates the anti-virus activity of cholesterol 25-hydroxylase.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamic regulatory mechanism of cholesterol 25-hydroxylase-mediated antiviral response in RNA virus infections.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Cholesterol 25-hydroxylase (CH25H), an interferon-stimulated gene (ISG), has been implicated in broad-spectrum antiviral immunity. Here, we identify CH25H as a potent suppressor of hepatitis B virus (HBV) replication that significantly outperforms IFN-α in reducing HBV DNA, pregenomic RNA (pgRNA), HBsAg, and HBeAg, without inducing cytotoxicity. However, CH25H is weakly expressed in hepatocytes and only modestly induced by type I interferon. We found that CH25H expression is tightly controlled by microRNAs, especially miR-7705, which is induced by IFN-α in a STAT1-dependent manner. miR-7705 directly targets the 3'UTR of CH25H, suppressing its expression and enhancing HBV replication. Knockdown of miR-7705 restores CH25H levels, enhances IFN-induced antiviral responses, and suppresses HBV replication in both transient transfection and infection models. Mechanistically, miR-7705 overexpression nullifies CH25H-mediated suppression of HBV, whereas this effect is abolished in CH25H-knockout cells, confirming the specificity of the miR-7705-CH25H axis. Furthermore, we demonstrate that this regulatory axis also governs CH25H-mediated restriction of RNA viruses, including EV71 and CVB3, suggesting its broad antiviral relevance. Importantly, antagonizing miR-7705 enhances the efficacy of IFN-based therapy against both DNA and RNA viruses. These findings reveal miR-7705 as a negative regulator of CH25H and position the miR-7705-CH25H axis as a promising target to improve antiviral immunity. IMPORTANCE: This study highlights the critical role of miR-7705 in regulating the antiviral effects of interferon (IFN) therapy, particularly in the context of chronic HBV infection. By identifying miR-7705 as a key modulator of CH25H, a protein essential for controlling HBV replication, our research provides new insights into the mechanisms that limit the effectiveness of IFN treatment. Targeting miR-7705 could improve the efficacy of IFN-based therapies, offering a potential strategy to better manage HBV and other viral infections. This research paves the way for developing adjunctive treatments that enhance the body's natural antiviral responses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.